Molecule Holdings Inc
Molecule Holdings Inc. engages in production and co-packing of cannabis-infused beverages in Canada. It also offers cannabis extracts, beverages, edibles, and topical products directly to provincial retailers. The company offers its beverage products under the PHRESH, KLÕN, EMBODY, and CANAJO brands. Molecule Holdings Inc. is based in Lansdowne, Canada.
Molecule Holdings Inc (EVRRF) - Net Assets
Latest net assets as of July 2023: $-5.63 Million USD
Based on the latest financial reports, Molecule Holdings Inc (EVRRF) has net assets worth $-5.63 Million USD as of July 2023.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($3.15 Million) and total liabilities ($8.78 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $-5.63 Million |
| % of Total Assets | -178.44% |
| Annual Growth Rate | N/A |
| 5-Year Change | -207.88% |
| 10-Year Change | -122.51% |
| Growth Volatility | 169.1 |
Molecule Holdings Inc - Net Assets Trend (2007–2022)
This chart illustrates how Molecule Holdings Inc's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Molecule Holdings Inc (2007–2022)
The table below shows the annual net assets of Molecule Holdings Inc from 2007 to 2022.
| Year | Net Assets | Change |
|---|---|---|
| 2022-10-31 | $-3.69 Million | -678.77% |
| 2021-10-31 | $638.39K | -81.42% |
| 2020-10-31 | $3.44 Million | -20.42% |
| 2019-10-31 | $4.32 Million | +26.08% |
| 2018-10-31 | $3.43 Million | -8.93% |
| 2017-10-31 | $3.76 Million | -71.97% |
| 2016-10-31 | $13.42 Million | +2.74% |
| 2015-10-31 | $13.06 Million | -16.16% |
| 2014-10-31 | $15.58 Million | -5.09% |
| 2013-10-31 | $16.41 Million | -29.70% |
| 2012-10-31 | $23.35 Million | -13.39% |
| 2011-10-31 | $26.96 Million | +19.90% |
| 2010-10-31 | $22.48 Million | +32.66% |
| 2009-10-31 | $16.95 Million | +17.44% |
| 2008-10-31 | $14.43 Million | -27.56% |
| 2007-10-31 | $19.92 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Molecule Holdings Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 1318951500.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (October 2022)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $8.73 Million | % |
| Other Comprehensive Income | $147.33K | % |
| Other Components | $614.04K | % |
| Total Equity | $-3.69 Million | 100.00% |
Molecule Holdings Inc Competitors by Market Cap
The table below lists competitors of Molecule Holdings Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
LENZING
BE:LEN
|
$222.23K |
|
BROWN NON VTG-B
BE:BF5B
|
$222.27K |
|
BankInv Glob AktAnsv Udv Akk A
CO:BAIGAAUAA
|
$222.52K |
|
INTERPARFUMS
STU:I8P
|
$222.52K |
|
STRATSSM Certificates series supplement 2006-2 Trust IC
NYSE:GJS
|
$222.10K |
|
2BTD
XETRA:2BTD
|
$221.71K |
|
INVESCO
BE:3IW
|
$221.54K |
|
BAVARIAN NORDIC (BV3.SG)
STU:BV3
|
$221.35K |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Molecule Holdings Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2021 to 2022, total equity changed from 638,388 to -3,694,772, a change of -4,333,160 (-678.8%).
- Net loss of 4,543,921 reduced equity.
- Other factors increased equity by 210,761.
Equity Change Factors (2021 to 2022)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-4.54 Million | -122.98% |
| Other Changes | $210.76K | +5.7% |
| Total Change | $- | -678.77% |
Book Value vs Market Value Analysis
This analysis compares Molecule Holdings Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2017-10-31 | $0.40 | $0.00 | x |
| 2018-10-31 | $0.37 | $0.00 | x |
| 2019-10-31 | $0.93 | $0.00 | x |
| 2020-10-31 | $0.05 | $0.00 | x |
| 2021-10-31 | $0.01 | $0.00 | x |
| 2022-10-31 | $-0.04 | $0.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Molecule Holdings Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 0.00%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -230.84%
- • Asset Turnover: 0.50x
- • Equity Multiplier: 0.00x
- Recent ROE (0.00%) is above the historical average (-81.79%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2007 | 0.00% | 0.00% | 0.00x | 1.02x | $-1.99 Million |
| 2008 | 0.00% | 0.00% | 0.00x | 1.01x | $-1.44 Million |
| 2009 | 0.00% | 0.00% | 0.00x | 1.01x | $-1.69 Million |
| 2010 | -10.41% | 0.00% | 0.00x | 1.01x | $-4.59 Million |
| 2011 | -3.33% | 0.00% | 0.00x | 1.03x | $-3.59 Million |
| 2012 | -24.43% | 0.00% | 0.00x | 1.03x | $-8.04 Million |
| 2013 | -26.30% | 0.00% | 0.00x | 1.06x | $-5.96 Million |
| 2014 | -15.71% | 0.00% | 0.00x | 1.05x | $-4.01 Million |
| 2015 | -34.08% | 0.00% | 0.00x | 1.05x | $-5.76 Million |
| 2016 | -8.22% | 0.00% | 0.00x | 1.04x | $-2.44 Million |
| 2017 | -284.73% | 0.00% | 0.00x | 1.08x | $-11.09 Million |
| 2018 | -10.10% | 0.00% | 0.00x | 1.10x | $-688.52K |
| 2019 | -67.63% | 0.00% | 0.00x | 1.17x | $-3.35 Million |
| 2020 | -57.52% | 0.00% | 0.00x | 1.59x | $-2.32 Million |
| 2021 | -766.21% | -1074.42% | 0.08x | 9.33x | $-4.96 Million |
| 2022 | 0.00% | -230.84% | 0.50x | 0.00x | $-4.17 Million |
Industry Comparison
This section compares Molecule Holdings Inc's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $548,450,613
- Average return on equity (ROE) among peers: -450.37%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Molecule Holdings Inc (EVRRF) | $-5.63 Million | 0.00% | N/A | $222.16K |
| Ascend Wellness Holdings Inc (AAWH) | $142.87 Million | -33.75% | 5.44x | $48.90 Million |
| AB Science S.A (ABSCF) | $10.73 Million | -252.65% | 3.71x | $39.89 Million |
| Alterola Biotech Inc (ABTI) | $4.85K | -2005.32% | 0.49x | $603.58K |
| Aurora Cannabis Inc (ACB) | $2.04 Billion | -34.08% | 0.34x | $199.15 Million |
| Acreage Holdings Inc (ACRDF) | $204.27 Million | -30.85% | 1.41x | $13.48K |
| Acura Pharmaceuticals Inc (ACUR) | $7.90 Million | -63.15% | 1.15x | $13.20K |
| Agra Ventures Ltd. (AGFAF) | $1.51 Million | -44.22% | 0.06x | $298.23K |
| Allergy Therapeutics plc (AGYTF) | $2.07 Million | -2084.75% | 31.32x | $25.30 Million |
| Aida Pharmaceuticals Inc (AIDA) | $6.67 Million | 24.51% | 2.78x | $1.80 |
| Adcock Ingram Holdings Limited (AIHLF) | $3.07 Billion | 20.55% | 0.55x | $85.61 Million |